

Development of Lead compounds as a Deubiquitinase USP1 Inhibitor for Non-Alcoholic Fat Liver Diseases Therapy

Yonsei University



METABOLIC	Lead
Product Type	Chemical - Small Molecule
Indication	1st indication : Non-Alcoholic Fat Liver Diseases (NAFLD)
Target	Ubiquitin-specific protease-1(USP1)
MoA(Mechanism of Action)	USP1 inhibitor → USP1 inhibition → Reduced expression of lipid accumulation related proteins → Amelioration of Metabolic diseases, such as NAFLD/NASH
Competitiveness	First in class Development a new therapeutic method of non-alcoholic fatty liver disease through an novel target
Development Stage	Lead
Route of Administration	Oral administration